Table 2.
Prognostic performance of cellular dissociation grading (CGD), Brandwein–Gensler (BG) histopathological risk score, and WHO grading in the TCGA-HNSC cohort (n = 311) and in the subcohorts of HPV-negative (n = 286) and HPV-positive (n = 45) tumors.
| Outcome | CDG (high vs. low) | BG score (high vs. int./low) | WHO grade (G3/G2 vs. G1) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | CI | P | HR | CI | P | HR | CI | P | |
| Univariate analysis | |||||||||
| PFI | 1.57 | 1.1–2.22 | 0.012 | 1.51 | 1.04–2.18 | 0.029 | 1.64 | 0.92–2.91 | 0.092 |
| OS | 1.64 | 1.19–2.26 | 0.0024 | 1.53 | 1.1–2.13 | 0.012 | 1.69 | 1.01–2.81 | 0.046 |
| HPV−: PFI | 1.4 | 0.96–2.03 | 0.08 | 1.42 | 0.96–2.12 | 0.081 | 1.63 | 0.91–2.92 | 0.097 |
| HPV−: OS | 1.48 | 1.05–2.08 | 0.025 | 1.38 | 0.96–1.97 | 0.079 | 1.69 | 1.01–2.83 | 0.047 |
| HPV+: PFI | 4.93 | 1.7–14.3 | 0.0034 | 2.71 | 0.87–8.42 | 0.084 | NAa | NAa | NAa |
| HPV+: OS | 5.05 | 1.87–13.67 | 0.0014 | 3.95 | 1.37–11.44 | 0.011 | NAa | NAa | NAa |
| Multivariate analysis | |||||||||
| PFI | 1.55 | 1.05–2.28 | 0.028 | 1.49 | 1–2.23 | 0.051 | 1.18 | 0.64–2.19 | 0.6 |
| OS | 1.74 | 1.21–2.49 | 0.0026 | 1.48 | 1.03–2.13 | 0.033 | 1.43 | 0.81–2.52 | 0.22 |
| HPV−: PFI | 1.37 | 0.92–2.06 | 0.12 | 1.3 | 0.84–2.01 | 0.24 | 1.1 | 0.59–2.06 | 0.76 |
| HPV−: OS | 1.51 | 1.04–2.18 | 0.03 | 1.24 | 0.83–1.84 | 0.29 | 1.24 | 0.7–2.21 | 0.46 |
| HPV+: PFI | 3.46 | 0.82–14.56 | 0.09 | 2.07 | 0.46–9.37 | 0.34 | NAa | NAa | NAa |
| HPV+: OS | 2.28 | 0.73–7.17 | 0.16 | 2.63 | 0.71–9.69 | 0.15 | NAa | NAa | NAa |
Univariate analysis of DFI and OS and multivariate analysis of DFI and OS including age (>61 vs. ≤61 years), sex (female, male), HPV status (HPV-positive, HPV-negative), localization (oropharynx, all other), AJCC stage (I–III, IV), and margin status (negative/close, positive).
Bold fonts indicate statistical significance.
HR hazard ratio, CI 95% confidence interval.
aAnalysis not feasible, because of low sample size (only a single tumor was HPV+ and G1).